Pre-Clinical White Matter Changes and Associated Connectivity Effects in Fabry Disease
Primary Purpose
Fabry Disease
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Functional MRI and fast bound-pool fraction imaging
Sponsored by
About this trial
This is an interventional basic science trial for Fabry Disease focused on measuring fabry, MRI (Magnetic resonance imaging), Fabry brain lesions
Eligibility Criteria
Fabry Cohort
Inclusion Criteria:
- Have Fabry Disease
- Must be 18yrs or older
Exclusion Criteria:
- Subjects who are claustrophobic
- have metal implants
- Cannot pass the MRI safety screening questionnaire.
Unaffected Controls
Inclusion Criteria:
- Must be 18yrs or older
- unaffected with Fabry Disease
- considered healthy with no previous history of stroke, multiple sclerosis, diabetes mellitus, or other neurologic disease.
Exclusion Criteria:
- Subjects who are claustrophobic
- have metal implants
- Cannot pass the MRI safety screening questionnaire.
Sites / Locations
- University of Utah
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Fabry
Arm Description
Must be 18 or older and able to have an MRI.
Outcomes
Primary Outcome Measures
FBFI MRI using advanced MRI technique
advanced quantitative MRI technique (FBFI) to detect and quantify brain lesion in patients with FD
Identify difference between patients with Fabry disease and healthy controls in brain function as measured and quantified by functional MRI
identify altered brain function
use FBFI and fMRI to map
together to map altered connectivity in response to brain lesions
Secondary Outcome Measures
Full Information
NCT ID
NCT03678324
First Posted
September 6, 2018
Last Updated
May 19, 2022
Sponsor
University of Utah
Collaborators
Genzyme, a Sanofi Company
1. Study Identification
Unique Protocol Identification Number
NCT03678324
Brief Title
Pre-Clinical White Matter Changes and Associated Connectivity Effects in Fabry Disease
Official Title
Pre-Clinical White Matter Changes and Associated Connectivity Effects in Fabry Disease
Study Type
Interventional
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
Completed
Study Start Date
January 27, 2020 (Actual)
Primary Completion Date
March 30, 2022 (Actual)
Study Completion Date
March 30, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Utah
Collaborators
Genzyme, a Sanofi Company
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this research project is:
to use an advanced quantitative MRI technique (FBFI) to detect and quantify brain lesion in patients with FD
to use fMRI to identify altered brain function
to use FBFI and fMRI together to map altered connectivity in response to brain lesions
Detailed Description
Fabry disease (FD) is a lysosomal storage disease caused by a deficiency in an enzyme that degrades components of the outer cell wall. A deficiency of this enzyme in humans has been associated with stroke. In males with FD, 6.9% have a stroke by 39 years of age. In females with FD, 4.3% have a stroke by 46 years of age.
Magnetic resonance imaging (MRI) is the main tool for studying stroke in FD. Importantly, MRI has identified other types of lesions in the brain beyond that caused by stroke. These additional lesions may herald stroke or be a different manifestation of FD in the brain. These lesions are seen in >50% of men and women with FD.
Diffusion-based imaging MRI has been the leading approach for studying these lesions in FD. However, these lesions that appear to be specific to FD are difficult to quantify, analyze, and interpret using this and other current MRI methods. The Investigators would like to use a form of MRI called fast bound-pool fraction imaging (FBFI), which is a technique better suited to capture and quantify these lesions, to study these lesions in patients with FD. In parallel, the investigators would like to use functional MRI (fMRI) to study how these lesions alter brain function and connectivity in FD. The combination of these techniques (FBFI + fMRI) will also provide us the opportunity to study brain plasticity in response to injury as Fabry disease is slowly progressive over decades allowing the brain to remodel connections to maintain function.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fabry Disease
Keywords
fabry, MRI (Magnetic resonance imaging), Fabry brain lesions
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
20 patients with Fabry and 20 unaffected
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Fabry
Arm Type
Other
Arm Description
Must be 18 or older and able to have an MRI.
Intervention Type
Other
Intervention Name(s)
Functional MRI and fast bound-pool fraction imaging
Other Intervention Name(s)
fmri, FBFI, Neuropsychological assessments
Intervention Description
Use a form of MRI called fast bound-pool fraction imaging (FBFI), which is a technique better suited to capture and quantify these lesions, to study these lesions in patients with FD. In parallel, we would like to use functional MRI (fMRI) to study how these lesions alter brain function and connectivity in FD.
Neuropsychological assessements will include Wechsler Adult Intelligence Scale, WAIS-III (Digit Span, Symbol-Digit/Coding, and Symbol Search), the Connors Continous Performance text (CPT-II). The Health Questionnaire form, the Center for Epidemiologic Studies Depression Scale (CES-D), the RAND 36-Item Health Survey.
Primary Outcome Measure Information:
Title
FBFI MRI using advanced MRI technique
Description
advanced quantitative MRI technique (FBFI) to detect and quantify brain lesion in patients with FD
Time Frame
6 months after enrollment closes
Title
Identify difference between patients with Fabry disease and healthy controls in brain function as measured and quantified by functional MRI
Description
identify altered brain function
Time Frame
6 months after enrollment closes
Title
use FBFI and fMRI to map
Description
together to map altered connectivity in response to brain lesions
Time Frame
6 months after enrollment closes
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Fabry Cohort
Inclusion Criteria:
Have Fabry Disease
Must be 18yrs or older
Exclusion Criteria:
Subjects who are claustrophobic
have metal implants
Cannot pass the MRI safety screening questionnaire.
Unaffected Controls
Inclusion Criteria:
Must be 18yrs or older
unaffected with Fabry Disease
considered healthy with no previous history of stroke, multiple sclerosis, diabetes mellitus, or other neurologic disease.
Exclusion Criteria:
Subjects who are claustrophobic
have metal implants
Cannot pass the MRI safety screening questionnaire.
Facility Information:
Facility Name
University of Utah
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84108
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
Aggregate data will be published.
Learn more about this trial
Pre-Clinical White Matter Changes and Associated Connectivity Effects in Fabry Disease
We'll reach out to this number within 24 hrs